Download PDF
Exp Clin Endocrinol Diabetes 2022; 130(S 01): S127-S136
DOI: 10.1055/a-1624-3631
German Diabetes Association: Clinical Practice Guidelines

Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People with Diabetes Mellitus

Joint Statement of the German Diabetes Society (DDG), The German Angiology Society (DGA) and The German Society for Interventional Radiology and Minimally-Invasive Therapy (DeGIR) German Society for Vascular Surgery and Vascular Medicine (DGG)
Bernd Balletshofer   *
1   Angiology Centre, Tübingen, Germany
,
Dittmar Böckler   *
2   Department of Vascular Surgery and Endovascular Surgery, University Hospital of Heidelberg, Heidelberg, Germany
,
Holger Diener   *
3   Department of Vascular Surgery and Endovascular Surgery, Buchholz Hospital, Buchholz, Germany
,
Jörg Heckenkamp   *
4   Department of Vascular Surgery, Niels Stensen Hospitals, Marienhospital Osnabrück, Osnabrück, Germany
,
Wulf Ito   *
5   Heart and Vascular Center Oberallgäu, Kempten, Germany
,
Marcos Katoh   *
12   Department of Diagnostic and Interventional Radiology, Helios Hospital, Krefeld, Germany
,
Holger Lawall   *
6   Joint practice Prof. Dr. C. Diehm/Dr. H. Lawall, Max Grundig Clinic Bühlerhöhe, Ettlingen, Germany
,
Nasser Malyar   *
7   Department of Cardiology I – Coronary Heart Disease, Heart Failure and Angiology, University Hospital, Münster, Germany
,
Yves Oberländer   *
8   Department of Internal Medicine 1 for Diabetology, Endocrinology, Cardiology and Angiology, Marienhospital, Stuttgart, Germany
,
Peter Reimer   *
9   Institute for Diagnostic and Interventional Radiology, Städtisches Krankenhaus, Karlsruhe, Germany
,
Kilian Rittig   *
10   Department of Internal Medicine IV, Angiology and Diabetology, Klinikum Frankfurt (Oder), Germany
,
Markus Zähringer   *
11   Department of Diagnostic and Interventional Radiology, Marienhospital, Stuttgart, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

This position paper is based on the current German and international guideline recommendations [1] [2] [3] and serves as a short, clinically-oriented guideline for the diagnosis and treatment of patients with diabetes mellitus and peripheral arterial disease (PAD).

Peripheral circulatory disorders of the pelvic and leg arteries are one of the complications patients with diabetic mellitus suffer from. The term covers stenoses, occlusions and – to a lesser extent – aneurysmal vascular changes of the pelvic leg arteries.

Arterial vascular lesions mostly occur in later life, however, people with diabetes mellitus are often affected prematurely. In these patients, the time of the initial manifestation also depends on the duration of the disease and the quality of metabolic control. Only 25% of affected patients have symptoms.

Especially in patients with diabetes mellitus, atheroma of the peripheral vessels is aggravated by chronic inflammatory vessel wall processes and hypercoagulability.

Second to nicotine abuse, diabetes is the most important risk factor for the occurrence of PAD [4].

Patients with diabetes have a 2 to 4-time higher risk of developing PAD than patients without diabetes.

Up to 30% of all patients with claudication and 50% of all patients with critical limb ischaemia (CLI) are people with diabetes mellitus [5].

PAD patients with diabetes have specific anatomical-morphological and clinical characteristics which must be considered in the diagnostic and therapeutic approach. Compared to people without diabetes mellitus, PAD in people with diabetes mellitus develops earlier, progresses more rapidly and changes over more frequently to critical limb ischaemia (CLI). Anatomically-morphologically, a multi-segmental manifestation is typical with long, calcified stenoses/occlusions of the lower leg arteries with insufficient collateral formation. Clinically, people with diabetes mellitus often first consult their doctors because of a critical ischaemia, in part because the intermittent claudication preceding a critical ischaemia and the pain at rest can remain masked for a long time by the diabetic sensory polyneuropathy. The prognosis regarding a life without amputations is poor for people with diabetes mellitus. This is due, on the one hand, to the high ischaemia and ulcer recurrence rates and the associated minor and major amputations, on the other hand it results from the high rate of comorbidities and co-prevalence of terminal organ damage such as cardiac and renal insufficiency, each of which on its own increases mortality.

The most significant consequences of diabetic peripheral circulatory disorders are foot lesions (ulcers and gangrene) and minor and major amputations as a result of ischaemic or neuro-ischaemic diabetic foot syndrome (DFS) ([Tab. 1]).

Tab. 1 Classification of PAD according to Fontaine and Rutherford.

Fontaine

Rutherford

Stage

Clinical picture

Degree

Category

Clinical picture

I

Asymptomatic

0

0

Asymptomatic

IIa

Walking distance>200 m

I

1

Mild IC

IIb

Walking distance<200 m

I

2

Moderate IC

I

3

Severe IC

III

Ischaemic pain at rest

II

4

Ischaemic pain at rest

IV

Ulcer, gangrene

III

5

Small patches necrosis

III

6

Large patches necrosis

IC=Intermittent claudication.

WHAT DOES IT MEAN?

  • The number of patients with PAD and diabetes is constantly increasing.

  • The risk of amputation in people with diabetes mellitus is significantly increased in the presence of PAD.

  • Timely detection of PAD reduces the amputation and cardiovascular event rates if treatment is in accordance with guidelines.

  • Interdisciplinary cooperation and rapid revascularisation are crucial in critical limb ischaemia.

* Authors in alphabetical order




Publication History

Article published online:
22 April 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Lawall H, Huppert P, Rümenapf G. S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der PAVK. AWMF-LL 065/003. 2015
    PubMed
  • 2 Aboyans V, Ricco JB, Bartelink MEL. et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Disease, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering arterosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J 2018; 39: 763-816
    CrossrefPubMedGoogle Scholar
  • 3 Hinchliffe RJ, Forsythe R, Apelquist J. et al. IWGDF Guideline on diagnosis, prognosis and management of peripheral arterial disease in patients with a foot ulcer and diabetes. Diabetes Metab Res Rev 2020; 36 (Suppl 1): e3276
    CrossrefPubMedGoogle Scholar
  • 4 Fowkes GFR, Rudan D, Rudan I. et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013; 382: 1329-1340
    CrossrefPubMedGoogle Scholar
  • 5 Malyar N, Freisinger E, Meyborg M. et al. Amputations and mortality in in-hospital treated patients with peripheral arterial disease and diabetic foot syndrome. J Diab Compl 2016; 30: 1117-1122
    CrossrefPubMedGoogle Scholar
  • 6 Cacoub PP, Bhatt DL, Steg PG. et al. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 2009; 30: 192-201
    CrossrefPubMedGoogle Scholar
  • 7 ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018; 379: 1529-1539
    CrossrefPubMedGoogle Scholar
  • 8 McNeil JJ, Wolfe R, Woods RL. et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Eng J Med. 2018
    PubMedGoogle Scholar
  • 9 CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339
    CrossrefPubMedGoogle Scholar
  • 10 Hiatt WR, Fowkes FG. Heizer G. EUCLID Trial Steering Committee and Investigators et al. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med 2017; 376: 32-40
    CrossrefPubMedGoogle Scholar
  • 11 Williams B, Mancia G, Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. EUR Heart J 2018; 39: 3021-3104
    CrossrefPubMedGoogle Scholar
  • 12 Soga Y, Iida O, Takahara M. et al. Beta-Blocker Treatment Does not worsen Critical Limb Ischemia in Patients Receiving Endovascular Therapy. J Arteroscler Thromb 2015; 22: 481-489
    CrossrefPubMedGoogle Scholar
  • 13 Cosentino F et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with EASD. Eur Heart J 2020; 41: 255–323
    PubMed
  • 14 Itoga NK, Taefik DS, Lee CK. et al. Association of Blood Pressure Measurements with Peripheral Artery Disease Events. Circulation 2018; 138: 1805-1814
    CrossrefPubMedGoogle Scholar
  • 15 Anand SS, Bosch J, Eikelboom JW. et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 219-229
    CrossrefPubMedGoogle Scholar
  • 16 Hsu CY, Chen YT, Su YW. et al. Statin therapy reduces future risk of lower limb amputation in patients with diabetes and peripheral artery disease. J Clin Endocrinol Metab 2017; 102: 2373-2381
    CrossrefPubMedGoogle Scholar
  • 17 Arya S, Khakharia A, Binney ZO. et al. Association of Statin Dose With Amputation and Survival in Patients With Peripheral Artery Disease. Circulation 2018; 137: 1435-1446
    CrossrefPubMedGoogle Scholar
  • 18 Momsen AH, Jensen MB, Norager CB. et al. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg 2009; 38: 463-474
    CrossrefPubMedGoogle Scholar
  • 19 Rajamani K, Colman PG, Li LP. et al. FIELD study investigators Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009; 373: 1780-1788
    CrossrefPubMedGoogle Scholar
  • 20 Bonaca MP, Nault P, Giugliano RP. et al. Low density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation 2018; 137: 338-350
    CrossrefPubMedGoogle Scholar
  • 21 Khan SZ, Rivero M, Nader ND. et al. Metformin Is Associated with Improved Survival and Decreased Cardiac Events with No Impact on Patency and Limb Salvage after Revascularization for Peripheral Arterial Disease. Ann Vasc Surg 2019; 55: 63-77
    CrossrefPubMedGoogle Scholar
  • 22 Bannister CA, Holden SE, Jenkins-Jones S. et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls?. Diabetes Obes Metab 2014; 16: 1165-1173
    CrossrefPubMedGoogle Scholar
  • 23 Dormandy JA, Charbonnel B, Eckland DJ. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289
    CrossrefPubMedGoogle Scholar
  • 24 Erdmann E, Dormandy JA, Massi-Benedetti M. et al. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49: 1772-1780
    PubMedGoogle Scholar
  • 24 Wilcox R, Bousser MG, Betteridge DJ. et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macrovascular Events04). Stroke 2007; 38: 865-873
    CrossrefPubMedGoogle Scholar
  • 26 Lincoff AM, Wolski K, Nicholls SJ. et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA 2007; 298: 1180-1188
    CrossrefPubMedGoogle Scholar
  • 27 Kernan WN, Viscoli CM, Furie KL. et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med 2016; 374: 1321-1331
    CrossrefPubMedGoogle Scholar
  • 28 Scirica BM, Braunwald E, Raz I. et al. Heart failure, saxagliptin and diabetes mellitus: observations from the saVor – tiMi 53 randomized trial. Circulation 2015; 132: e198
    CrossrefPubMedGoogle Scholar
  • 29 White WB, Cannon CP, Heller SR. et al. alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335
    CrossrefPubMedGoogle Scholar
  • 30 Zannad F, Cannon CP, Cushman WC. et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXaMinE: a multicentre, randomised, double-blind trial. Lancet 2015; 385: 2067-2076
    CrossrefPubMedGoogle Scholar
  • 31 Green JB, Bethel MA, Armstrong PW. et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232-242
    CrossrefPubMedGoogle Scholar
  • 32 Rosenstock J. CAROLINA®: Cardiovascular safety and renal microvascular outcome with linagliptin in patients with T2D at high vascular risk. Oral presentation at the 79th Scientific Sessions of the American Diabetes Association (ADA), 10 June 2019. San Francisco, CA, USA:
    Google Scholar
  • 33 Marso SP, Daniels GH, Brown-Frandsen K. et al. Liraglutide and Cardiovascular Outcomes in Type2 Diabetes. N Engl J Med 2016; 375: 311-322
    Google Scholar
  • 34 Marso SP, Bain SC, Consoli A. SUSTAIN-6 Investigators. et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016; 375: 1834-1844
    Google Scholar
  • 35 Gerstein HC, Colhoun HM, Dagenais GR. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial. Lancet 2019; 394: 121-130
    Google Scholar
  • 36 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128
    Google Scholar
  • 37 Wanner C, Inzucchi SE, Zinman B. et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375: 323-334
    CrossrefPubMedGoogle Scholar
  • 38 Neal B, Perkovic V, Matthews DR. Canagliflozin and Cardiovascular and Renal Events in Type2 Diabetes. N Engl J Med 2017; 377: 2099
    CrossrefPubMedGoogle Scholar
  • 39 Wiviott SD, Raz I, Bonaca MP. et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380: 347-357
    CrossrefPubMedGoogle Scholar
  • 40 Perkovic V, Jardine MJ, Neal B. et al. CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 13: 2295-2306
    CrossrefPubMedGoogle Scholar
  • 41 Holman RR, Coleman RL, Chan JCN. et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucosetolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5: 877-886
    CrossrefPubMedGoogle Scholar
  • 42 Gerstein HC, Bosch J, Dagenais GR. et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328
    CrossrefPubMedGoogle Scholar
  • 43 Schaper NC, van Netten JJ, Apelqvist J. et al. Pracitcal Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diabetes Metab Res Rev 2020; 36: e 3266
    CrossrefPubMedGoogle Scholar
  • 44 Greenhalgh RM, Belch JJ, Brown LC. et al. The adjuvant benefit of angioplasty in patients with mild to moderate intermittent claudication managed by supervised exercise, smoking cessation advice and best medical therapy: results from two randomised trials for stenotic femoropopliteal and aortoiliac arterial disease. Eur J Vasc Endovasc Surg 2008; 36: 680-688
    CrossrefPubMedGoogle Scholar
  • 45 Kersting J, Kamper L, Das M. et al. Leitliniengerechte Therapie der pAVK – aktuelle Studienlage und Ausblick. Fortschr Röntgenstr 2019; 191: 311-322
    PubMedGoogle Scholar
  • 46 Lawall H, Huppert P, Zemmrich CS. et al. S3-Leitlinie PAVK – Diagnostik, Therapie und Nachsorge der peripher arteriellen Verschlusskrankheit. VASA 2016; 45: 1-100
    CrossrefPubMedGoogle Scholar
  • 47 Gerhard-Hermann MD, Gornik HL, Barrett C. et al. 2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery disease: executive summary. Vasc Med 2017; 22: NP1-NP43
    CrossrefPubMedGoogle Scholar
  • 48 Laird JR, Katzen BT, Scheinert D. et al. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries for patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther 2012; 19: 1-9
    CrossrefPubMedGoogle Scholar
  • 49 Schlager O, Gschwandtner ME, Willfort-Ehringer A. et al. Drug coated balloons in the superficial femoral artery. J Cardiovasc Surg 2018; 59: 60-69
    PubMedGoogle Scholar
  • 50 Dake MD, Ansel GM, Jaff MR. et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver-PTX randomized trial. Circulation 2016; 133: 1472-1483
    CrossrefPubMedGoogle Scholar
  • 51 Katsanos K, Spiliopoulos S, Kitrou P. et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2018; 18: 1-13
    PubMedGoogle Scholar
  • 52 Empfehlung des BfArM. Empfehlung für die Verwendung von Paclitaxelbeschichteten Stents (DES) und Ballons (DCB) in der Behandlung der peripheren arteriellen Verschlusskrankheit (pAVK). Referenz Nr. 00092/19. Stand 13.06.2019
    PubMed
  • 53 https://www.fda.gov/medical-devices/letters-health-care-providers/august-7-2019-update-treatment-peripheral-arterial-disease-paclitaxelcoated-balloons-and-paclitaxel
    PubMed
  • 54 Bundesinstitut für Arzneimittel und Medizinprodukte. Sicherheitshinweis: Mit Paclitaxel beschichtete Ballons und Paclitaxel eluierende Stents. 2020 www.bfarm.de 08249-20_kundeninfo_de
    PubMed
  • 55 Hinchliffe RJ, Andros G, Apelqvist J. A systematic review of the effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral arterial disease. Diabetes Metab Res Rev 2012; 28: 179-217
    CrossrefPubMedGoogle Scholar
  • 56 Spreen MI, Martens JM, Knippenberg B. et al. Long-term follow-up of the PADI trial: percutaneous transluminal angioplasty versus drug-eluting stents for infrapopliteal lesions in critical limb ischemia. J Am Heart Assoc 2017; 6: e004877
    CrossrefPubMedGoogle Scholar
  • 57 Langhoff R, Behne A, Buschmann E. Promising role of drug-coated balloons in the tibial vessels?. J Cardiovasc Surg 2018; 57: 667-676
    PubMedGoogle Scholar
  • 58 Katsanos K, Spiliopoulos S, Kitrou P. et al. Risk of death and amputation with use of paclitaxel-coated balloons in the infrapopliteal arteries for treatment of critical limb ischemia: a systematic review and meta-analysis of randomized controlled trials. J Vasc Interv Radiol 2020; 31: 202-212
    CrossrefPubMedGoogle Scholar
  • 59 Medizinischer Dienst des Spitzenverbandes Bund der Krankenkassen (MDS). Drug Eluting Balloons bei pAVK-Nutzenbewertung und Indikationskriterien (22.10.202). Im Internet (Stand: 01.09.2021) https://www.mds-ev.de/fileadmin/dokumente/Publikationen/GKV/Methodik/GA_DEB_pAVK_Update_201022.pdf
    PubMed
  • 60 Matsuoka EK, Hasebe T, Ishii R. et al. Comparative performance analysis of interventional devices for the treatment of ischemic disease in below‑the-knee lesions: a systematic review and meta‑analysis. Cardiovasc Interv and Ther 2022; 37: 145-157
    CrossrefPubMedGoogle Scholar
  • 61 Manzi M. Innovations in the management of the diabetic foot. J Cardiovasc Surg 2018; 59: 653-654
    CrossrefPubMedGoogle Scholar
  • 62 Walker CM. Tibiopedal access for crossing of infrainguinal artery occlusions: a prospective multicenter observational study. J Endovasc Ther 2016; 23: 839-846
    CrossrefPubMedGoogle Scholar
  • 63 Bundesärztekammer, Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der wissenschaftlichen medizinischen Fachgesellschaften (AWMF). S3-Leitlinie „Nierenerkrankungen bei Diabetes im Erwachsenenalter“. Nationale Versorgungsleitlinie. AWMF-Leitlinien-Register Nr. nvl/001d 2015.
    PubMed
  • 64 Safian RD. CO2 angiography: colorless, odorless but definitely not useless. Catheter Cardiovasc Interv 2017; 90: 449-450
    CrossrefPubMedGoogle Scholar
  • 65 Conte MS, Bradbury AW, Kolh P. GVG Writing Group. et al. Global vascular guidelines on themanagement of chronic limb-threatening ischemia. J Vasc Surg 2019; 69: 3S-125S.e40
    CrossrefPubMedGoogle Scholar
  • 66 Forsythe R, Apelqvist J, Boyko EJ. et al. Effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral artery disease: A systematic review. Diabetes Metab Res Rev 2020; e3279
    CrossrefPubMedGoogle Scholar
  • 67 Hicks C, Najafian A, Farber A. et al. Diabetes does not worsen outcomes following infrageniculate bypass or endovascular intervention for patients with critical limb ischemia. J Vasc Surg 2016; 64: 1667-1674.e1
    CrossrefPubMedGoogle Scholar
  • 68 Hock C, Betz T, Töpel I. et al. A comparison of tibial and peroneal venous and HePTFE bypasses in diabetics with critical limb ischemia. Surgeon 2017; 15: 69-75
    CrossrefPubMedGoogle Scholar
  • 69 Bonaca MP, Bauersachs RM, Anand SS. et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med 2020; 382: 1994-2004
    CrossrefPubMedGoogle Scholar